Glycoprotein targeted therapeutics: a new era of anti‐herpes simplex virus‐1 therapeutics

Abstract excerpt

Herpes simplex virus type-1 (HSV-1) is among the most common human pathogens worldwide. Its entry into host cells is an intricate process that relies heavily on the ability of the viral glycoproteins to bind host cellular proteins and to efficiently mediate fusion of the virus envelope with the cell membrane. Acquisition of HSV-1 results in a lifelong latent infection. Because of the cycles of reactivation from a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Herpesvirus Infections and Treatments
• Share to Toxin Mechanisms and Immunotoxins
• Share to Virus-based gene therapy research